Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Next Previous
Trial Profile

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reparixin (Primary)
  • Indications Delayed graft function
  • Focus Therapeutic Use
  • Sponsors Dompe Farmaceutici

Most Recent Events

  • 25 May 2021 Primary endpoint (Proportion of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 36514 Days After Transplant.) has not been met, according to results published in the American Journal of Transplantation.
  • 25 May 2021 Results assessing efficacy and safety of Reparixin in patients who were insulin independent Day 365 after TPIAT, published in the American Journal of Transplantation.7
  • 12 Jun 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top